Business & Finance
Fuzeon maker reports strong Q4 and year-end results
Published in Hepatitis Weekly, September 6th, 2004
Total reported company revenue for the 14-week quarter ending July 2, 2004 was a record $157.7 million, up $42.3 million or 37% from $115.4 million in the prior year's 13-week fourth quarter.
Operating income as reported was a record $3.2 million for the quarter, up 48% from last year's fourth quarter. Net income as reported was a record $2.0 million, or $0.16 per share, compared to $1.4 million or $0.11 per share in last year's fourth quarter.
Henry F. Blissenbach, Chronimed's chairman and CEO, commented, "We are quite...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2004-09-06)
More Articles from Hepatitis Weekly
- Chronic Liver Disease
Non-invasive elastometry is a valuable tool for staging liver fibrosis - Immunology
Interferon-gamma signals slow progression in hepatitis C-infected patients - Immunosuppression
Rapid steroid withdrawal is appropriate for HCV-positive kidney recipients - Transplant Medicine
Race affects the outcomes of patients awaiting liver transplantations - Viral Epidemiology
A new assay distinguishes hepatitis B virus genotype A subtypes - AIDS/HIV Vaccine
Hemagglutinating virus protein induces immune response with HIV vaccine - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
